<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014080416090N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-10-04</date_registration>
      <primary_sponsor>Dental Branch Islamic Azad University of Tehran</primary_sponsor>
      <public_title>Comparison the efficacy of Triamcinolone Acetonide 0.1 % in Orabase with it's nanoliposomal carriers formulation on oral Lichen Planus patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the efficacy of Triamcinolone Acetonide 0.1 % in Orabase with it's nanoliposomal carriers formulation on oral Lichen Planus patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/15155</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Lichen Planus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Triamcinolone Acetonide 0.1% with nanoliposomal carriers in Orabase, Oral paste, three times a day for a month. Intervention 2: Control group: Triamcinolone Acetonide 0.1% in Orabase, Oral paste, three times a day for a month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary>      Abstract:&lt;br /&gt;&#13;
Background and Aim: Lichen planus (LP) is a chronic mucocutaneous disease, with different clinical subtypes. The erythematous-ulcerative type is accompanied by pain and burning sensation. Topical or systemic corticosteroid therapy is among the common treatments. No evidence is available supporting the superiority of any specific type or dose of treatment. Nano-drugs are recently used for the management of oral lesions. This study sought to compare the anti-inflammatory effects of 0.1% triamcinolone acetonide in Orabase® with and without nanoliposomal carriers on oral lichen planus (OLP).&lt;br /&gt;&#13;
Materials and Methods: This randomized clinical trial was performed on 40 patients with erythematous-ulcerative OLP.  Formulations of 0.1% Triamcinolone acetonide with and without nanoliposomal carriers in Orabase were used 3 times a day for a month in case and control groups, respectively. Pain intensity by linear Visual Analog Scale (0-10) and cross sectional area of the lesions by a grid paper (mm2) were measured before and one, two and four weeks after treatment. Data were analyzed using t-test, chi-square, Fisher’s Exact, Mann-Whitney and Wilcoxon Singed-Rank tests.&lt;br /&gt;&#13;
Results: Although the pain intensity and size of oral lesions decreased statistically by each drug formulation (P≤0.001), there were no significant differences between the two formulations after one, two and four weeks of treatment (P &gt;0.05).&lt;br /&gt;&#13;
Conclusion: Based on the results, the efficacy of the two formulations is similar for OLP. More investigations are required on topical drugs to obtain more efficient formulations.&lt;br /&gt;&#13;
Keywords: Oral lichen planus, Triamcinolone acetonide, Nanoliposomal carriers, Orabase, Pain, area of lesion, Formulation&lt;br /&gt;&#13;
     </results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Arash Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Oral Medicine Department, No. 4, 10th Neyestan, Pasdaran St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19585175</zip>
        <telephone>+98 21 2258 0925</telephone>
        <email>a_azizi@dentaliau.ac.ir</email>
        <affiliation>Dental Branch Islamic Azad University of Tehran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Arash Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 4, 10th Neyestan, Pasdaran St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 2258 0925</telephone>
        <email>a_azizi@dentaliau.ac.ir</email>
        <affiliation>Dental Branch Islamic Azad University of Tehran</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion Criteria: All referral patients to Oral Medicine Department of Dental  Branch, Islamic Azad University of Tehran with symptomatic oral lesions suspected of Lichen Planus; with confirmed diagnosis  clinically and histologically  of atrophic or erosive oral Lichen Planus. &#13;
 Exclusion Criteria: presence of dysplasia on histological examination; pregnancy; nursing; dysfunction of immune system(organ transplantation, lupus erythematous, ulcerative colitis); hematologic diseases; systemic diseases; history of systemic or topical corticosteroid therapy for Lichen Planus in the past month; Lichenoid reactions due to drug use or restorative materials.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Papulosquamous disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Triamcinolone Acetonide 0.1% with nanoliposomal carriers in Orabase, Oral paste, three times a day for a month</i_keyword>
      <i_keyword>Control group: Triamcinolone Acetonide 0.1% in Orabase, Oral paste, three times a day for a month</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: before treatment, 1, 2 and 4 weeks after treatment. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Area of the erythematous-erosive lesion. Timepoint: before treatment, 1, 2 and 4 weeks after treatment. Method of measurement: mm2.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dental Branch Islamic Azad University of Tehran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-09-24</approval_date>
        <contact_name>Ethics committee of Dental Branch, Islamic Azad University of Tehran</contact_name>
        <contact_address>No. 4, 10th Neyestan, Pasdaran St. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
